CIK 0001658551
- Non-accelerated filer
- Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464600503
- Phone
- +1 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | Klee Justin B. Co-Chief Executive Officer | Sale 10b5-1 | −37,483 | $29.39 | $1.1M | 3,575,573 |
| 2026-11-09 | Klee Justin B. Co-Chief Executive Officer | Sale 10b5-1 | −62,517 | $30.11 | $1.9M | 3,513,056 |
| 2026-09-10 | Klee Justin B. Co-Chief Executive Officer | Sale | −29,025 | $32.13 | $933K | 3,614,495 |
| 2026-09-10 | Klee Justin B. Co-Chief Executive Officer | Sale | −1,439 | $33.16 | $48K | 3,613,056 |
| 2026-08-18 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +60,039 | 3,643,520 | ||
| 2026-03-05 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +248,865 | 3,583,481 | ||
| 2026-03-05 | Klee Justin B. Co-Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +373,295 | 373,295 | ||
| 2026-03-02 | Klee Justin B. Co-Chief Executive Officer | Sale | −29,282 | $14.47 | $424K | 3,334,616 |
| 2026-02-02 | Klee Justin B. Co-Chief Executive Officer | Sale | −15,500 | $14.69 | $228K | 3,363,898 |
| 2026-01-16 | Klee Justin B. Co-Chief Executive Officer | Option exercise | +2,847 | $7.57 | $22K | 3,381,393 |
| 2026-01-16 | Klee Justin B. Co-Chief Executive Officer | Sale | −1,995 | $13.89 | $28K | 3,379,398 |
| 2026-01-16 | Klee Justin B. Co-Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −2,847 | 0 | ||
| 2026-01-15 | Klee Justin B. Co-Chief Executive Officer | Option exercise | +197,153 | $7.57 | $1.5M | 3,514,739 |
| 2026-01-15 | Klee Justin B. Co-Chief Executive Officer | Sale | −136,193 | $13.58 | $1.8M | 3,378,546 |
| 2026-01-15 | Klee Justin B. Co-Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −197,153 | 2,847 | ||
| 2026-01-06 | Klee Justin B. Co-Chief Executive Officer | Sale | −7,715 | $11.09 | $86K | 3,317,586 |
| 2025-09-30 | Klee Justin B. Co-Chief Executive Officer | Sale | −29,775 | $14.37 | $428K | 3,325,501 |
| 2025-09-30 | Klee Justin B. Co-Chief Executive Officer | Sale | −200 | $15.01 | $3K | 3,325,301 |
| 2025-03-31 | Klee Justin B. Co-Chief Executive Officer | Sale | −21,490 | $3.46 | $74K | 3,355,276 |
| 2025-03-06 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +180,118 | 3,376,766 |
Page 1 of 3 · 47 trades